| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/23/2011 | EP2287314A1 Streptococcus pyogenes antigens |
| 02/23/2011 | EP2287313A1 Streptococcus pyogenes antigens |
| 02/23/2011 | EP2287312A1 Streptococcus pyogenes antigens |
| 02/23/2011 | EP2287311A1 Streptococcus pyogenes antigens |
| 02/23/2011 | EP2287300A1 Bacterial toxin vaccine |
| 02/23/2011 | EP2287288A1 Animal protein free media for cultivation of cells |
| 02/23/2011 | EP2287285A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/23/2011 | EP2287199A2 Anti-alpha V beta 6 antibodies |
| 02/23/2011 | EP2287198A2 Anti-alpha V beta 6 antibodies |
| 02/23/2011 | EP2287196A2 Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| 02/23/2011 | EP2287194A2 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
| 02/23/2011 | EP2287193A1 Antibody molecules having specificity for human IL-1 beta |
| 02/23/2011 | EP2287192A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 02/23/2011 | EP2287191A2 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| 02/23/2011 | EP2287190A2 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| 02/23/2011 | EP2287186A1 Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| 02/23/2011 | EP2287185A2 High affinity TCR proteins and methods |
| 02/23/2011 | EP2287182A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287181A2 Differential in tumour gene products and use of same |
| 02/23/2011 | EP2287177A2 Streptococcus agalactiae antigens I + II |
| 02/23/2011 | EP2287175A2 Novel chemokine binding peptides capable of modulating the biological activity of chemokines |
| 02/23/2011 | EP2286844A2 Antibody-drug conjugates and methods |
| 02/23/2011 | EP2286841A1 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| 02/23/2011 | EP2286835A1 Type I interferon blocking agents for prevention and treatment of psoriasis |
| 02/23/2011 | EP2286834A2 Use of skin penetration enhancers and barrier disruption agents to enhance transcutaneous immune response |
| 02/23/2011 | EP2286833A2 Peptides for desensibilization against allergens |
| 02/23/2011 | EP2286832A1 Bacterial compositions for the treatment of cancer |
| 02/23/2011 | EP2286831A1 A method of inducing a CTL response |
| 02/23/2011 | EP2286830A2 Composition comprising vlp and amyloid-beta peptide |
| 02/23/2011 | EP2286799A2 Microspheres for active embolization |
| 02/23/2011 | EP2286231A1 Hematopoietic cells expressing the protein susd3 and ligands for the protein susd3 |
| 02/23/2011 | EP2286220A2 Methods for predicting patient response to modulation of the co-stimulatory pathway |
| 02/23/2011 | EP2285964A1 Phage lambda display constructs |
| 02/23/2011 | EP2285952A2 Novel fusion proteins and use thereof for preparing hepatitis c vaccines |
| 02/23/2011 | EP2285833A1 AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| 02/23/2011 | EP2285409A1 Il-1 alpha abs and methods of use |
| 02/23/2011 | EP2285408A2 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| 02/23/2011 | EP2285407A2 Zero-valent metallic treatment system and its applicaton for removal and remediation of polychlorinated biphenyls |
| 02/23/2011 | EP2285405A2 Vaccine compositions and methods |
| 02/23/2011 | EP2285404A1 Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose |
| 02/23/2011 | EP2285403A2 Human monoclonal antibodies against human chemokine receptor ccr7 |
| 02/23/2011 | EP2285397A2 Immunotherapies employing self-assembling vaccines |
| 02/23/2011 | EP2046378B9 Use of bacterial polysaccharides for biofilm inhibition |
| 02/23/2011 | EP1928492B1 Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
| 02/23/2011 | EP1831257B1 Humanized antibody specific for tumor necrosis factor-alpha |
| 02/23/2011 | EP1801209B1 Modified human hepatitis c virus genomic rna having autonomous replicative competence |
| 02/23/2011 | EP1542723B1 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| 02/23/2011 | EP1523497B1 Hsp70 from arthrobacter |
| 02/23/2011 | EP1135504B1 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 02/23/2011 | EP1113819B1 Antibody directed enzyme prodrug therapy (adept) with glucuronidase |
| 02/23/2011 | EP0912205B1 Method of preparing a composite bone graft |
| 02/23/2011 | CN1902312B Method of constructing transgenic dendritic cell |
| 02/23/2011 | CN101981187A Partial peptide of Survivin presented on MHC class II molecule and use thereof |
| 02/23/2011 | CN101981182A Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use therof |
| 02/23/2011 | CN101981056A Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof |
| 02/23/2011 | CN101981055A Anti-CD79B antibodies and immunoconjugates and methods of use |
| 02/23/2011 | CN101981053A Pegylated Abeta FAB |
| 02/23/2011 | CN101981052A Compositions, methods and kits |
| 02/23/2011 | CN101980723A Antibodies to clostridium difficile spores and uses thereof |
| 02/23/2011 | CN101980722A Compositions and methods for crystallizing antibodies |
| 02/23/2011 | CN101980721A Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same |
| 02/23/2011 | CN101980720A PCV2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
| 02/23/2011 | CN101980705A Use of benzophenone derivative or salt thereof and TNF alpha inhibitor in combination and pharmaceutical composition containing the derivative or salt thereof and the inhibitor |
| 02/23/2011 | CN101980017A Anti-TNF antibodies, compositions, methods and uses |
| 02/23/2011 | CN101979593A Immunotoxin, and preparation method and use thereof |
| 02/23/2011 | CN101979581A S7 gene and coded recombinant protein of grass carp reovirus strain, and acquisition method and application thereof |
| 02/23/2011 | CN101979566A Sulpho-oligodeoxynucleotide with immunostimulation activities and application thereof |
| 02/23/2011 | CN101979542A Preparation method and application of CpG motif-containing nucleotide sequence |
| 02/23/2011 | CN101979519A Method for preparing pseudorabies vaccines |
| 02/23/2011 | CN101979515A Animal rabies virus and vaccine and production method thereof |
| 02/23/2011 | CN101979514A Virus and vaccine of porcine reproductive and respiratory syndrome and preparation method of same |
| 02/23/2011 | CN101979513A Duck-origin paramyxovirus attenuated lapinized Chineses (LC) strain and application thereof to the preparation of vaccines |
| 02/23/2011 | CN101979504A Yersinia pestis ghost, preparation method thereof, and application of Yersinia pestis ghost serving as vaccine |
| 02/23/2011 | CN101979503A Recombinant brucella for expressing Asia type-I foot and mouth disease virus VP1 genes and method for producing vaccines thereof |
| 02/23/2011 | CN101979502A Recombinant brucella expressing VP1 gene of O-type foot-and-mouth disease virus and method for producing vaccines thereof |
| 02/23/2011 | CN101979501A Recombinant Salmonella choleraesuis for expressing surface antigen gene sao of streptococcus suis type 2, vaccine and application |
| 02/23/2011 | CN101979412A IL-18 binding proteins |
| 02/23/2011 | CN101979405A Immune dominant HLA-A3 super-type restrictive CTL epitope of hepatitis B virus core antigen and identification method and application thereof |
| 02/23/2011 | CN101979404A Conserved neutralizing epitope mimic peptide of H5 subtype avian influenza viruses and use thereof |
| 02/23/2011 | CN101979095A Treatment and diagnosis of macrophage mediated disease |
| 02/23/2011 | CN101979089A Bovine staphylococcus aureus mastitis inactivated vaccine and preparation method thereof |
| 02/23/2011 | CN101978948A Low-temperature emulsification process of animal oil emulsion inactivated vaccines |
| 02/23/2011 | CN101058608B Human anti-Abeta(1-32) amyloid antibody, purifying method and use thereof |
| 02/22/2011 | US7893237 Haemophilus influenzae type IV pili |
| 02/22/2011 | US7893230 Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| 02/22/2011 | US7893219 Protective anti-glucan antibodies with preference for β-1,3- glucans |
| 02/22/2011 | US7893217 Isolated human antibodies that bind epitopes on RG1 |
| 02/22/2011 | US7893216 Anti-human trail receptor DR5 monoclonal antibody (AD5-10), method thereof and use of the same |
| 02/22/2011 | US7893215 Agonist antibodies to IL-23 receptor |
| 02/22/2011 | US7893213 Antibodies to activin receptor |
| 02/22/2011 | US7893211 Polypeptide fusion comprising three nonoverlapping domains for use as tool in identifying modulator for enhancing immune response; immunization; |
| 02/22/2011 | US7893205 Hemopoietin receptor protein, NR12 |
| 02/22/2011 | US7893204 Attractin/mahogany-like polypeptides |
| 02/22/2011 | US7893202 Post-translational modifications and Clostridial neurotoxins |
| 02/22/2011 | US7893199 Peptides having neutrophil-stimulating activity |
| 02/22/2011 | US7893083 Using imiquimod; rubbing into surface |
| 02/22/2011 | US7892828 Method of identifying a MHC class I restricted T cell response |
| 02/22/2011 | US7892754 Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof |
| 02/22/2011 | US7892727 Chemokine-binding protein and methods of use |
| 02/22/2011 | US7892578 Treatment of hematologic disorders |